IP Group Plc

IP Group reported a small overall loss for the first six months, with David Baynes calling it about GBP 43 million, and noted NAV per share moved from 97p to 96p at the half year before recovering to about GBP 1 after period end. Gross cash was GBP 237 million, up 47% year over year, and cash proceeds in the period were GBP 30 million, which management said was 9x the first half of 2024. Net overheads were down about 14% period-on-period, with the company still targeting a 23% reduction versus 2023 levels to around GBP 16.5 million net by year-end. Forward targets stayed unchanged: GBP 250 million of exits by end-2027, GBP 50 million of realizations for FY25 as an internal target, and a buyback policy using 50% of realizations this year while the discount remains above 20%.

Gregory Smith framed the half as a period of strong progress, with public markets contributing positively and several private portfolio names also advancing. He highlighted Hinge Health’s IPO, Oxford Nanopore’s better-than-expected first-half results, and a pipeline of milestones running through 2027. His tone was constructive and confident, especially around exits, NAV stability, and the prospect of securing at least one new private scale-up mandate by the full-year results.

Dave Baynes said the balance sheet remained strong, citing GBP 237 million of cash, a small half-year loss of about GBP 43 million, and NAV per share of 96p at the half before recovering to about GBP 1 after period end. He walked through the valuation movements, noting FX headwinds of GBP 14 million and provisions tied mainly to Oxa and Artios where funding rounds were not yet complete, while also saying the loss had been eliminated since year-end through gains in Nanopore and Hinge. He also detailed cash use: GBP 35 million invested, GBP 30 million realized, GBP 25 million spent on buybacks, and overheads trending toward the targeted GBP 16.5 million net.

Analysts focused on whether U.S. research funding uncertainty could benefit the U.K., but management said any effect would likely be long term rather than immediate. Questions also probed Hinge Health monetization, Nanopore selling down, the licensing portfolio, buyback policy, Oxa’s valuation, and the rationale for the GBP 250 million exit target; management consistently pointed to liquidity, valuation discipline, and internal projections. On licensing, Dave Baynes said the portfolio is historically small, with roughly GBP 500,000 to GBP 700,000 of annual income and possible upside over the next 2 to 3 years if a few larger licenses succeed.